Latest Quarterly Sales News

Rare Foods Australia reports an 18% biomass increase and $440k in cost savings, while launching its Subsea Estate brand and securing a $2.1M R&D refund to support growth.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Tartana Minerals reports robust copper sulphate sales and completes a significant acquisition, positioning itself as a leading explorer and developer in Far North Queensland.

Constellation Technologies reports a slight decline in quarterly sales but marks a strategic breakthrough by deploying its Callisto Food Safety & Compliance system into the Aged Care sector, positioning itself for growth in a highly regulated market.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Pure Hydrogen advances its zero-emission vehicle strategy with key deliveries, US partnerships, and a planned demerger of its natural gas assets into Eastern Gas Limited.

Australian Dairy Nutritionals Limited reports improved cash flow in Q2 FY25 and prepares for the strategic launch of its premium Future brand in China, aiming to reshape its growth trajectory.

Vintage Energy reported a 105% jump in quarterly sales revenue driven by a 90% increase in production, despite operational challenges at its Odin-2 well and the termination of a merger proposal with Galilee Energy.

First Graphene Limited reports a robust December quarter with new patents, expanded distribution networks, and advancing commercial trials, positioning the company on a path to cash breakeven.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

ReNerve Limited has reported a remarkable 260% increase in quarterly sales following its successful IPO, alongside strategic distribution deals in Hong Kong and the Middle East. The company is poised for further growth with upcoming clinical data and product developments.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.